A PAX3/BRN2 rheostat controls the dynamics of BRAF mediated MITF regulation in MITFhigh/AXLlow melanoma

The BRAF kinase and the MAPK pathway are targets of current melanoma therapies. However, MAPK pathway inhibition results in dynamic changes of downstream targets that can counteract inhibitor‐action not only in during treatment, but also in acquired resistant tumours. One such dynamic change involves the expression of the transcription factor MITF, a crucial regulator of cell survival and proliferation in untreated as well as drug‐addicted acquired resistant melanoma. Tight control over MITF expression levels is required for optimal melanoma growth, and while it is well established that the MAPK pathway regulates MITF expression, the actual mechanism is insufficiently understood. We reveal here, how BRAF through action on the transcription factors BRN2 and PAX3 executes control over the regulation of MITF expression in a manner that allows for considerable plasticity. This plasticity provides robustness to the BRAF mediated MITF regulation and explains the dynamics in MITF expression that are observed in patients in response to MAPK inhibitor therapy.

[1]  K. Flaherty,et al.  Toward Minimal Residual Disease-Directed Therapy in Melanoma , 2018, Cell.

[2]  R. Sturm,et al.  BRN2, a POUerful driver of melanoma phenotype switching and metastasis , 2018, Pigment cell & melanoma research.

[3]  T. Graeber,et al.  Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress. , 2018, Cancer cell.

[4]  Huadong Liu,et al.  ERK-mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma , 2018, Nature Communications.

[5]  F. Al-Ejeh,et al.  MITF and BRN2 contribute to metastatic growth after dissemination of melanoma , 2017, Scientific Reports.

[6]  E. Rozeman,et al.  Cancer Drug Addiction is Relayed by an ERK2-Dependent Phenotype Switch , 2017, Nature.

[7]  D. Lipsker,et al.  MITF-High and MITF-Low Cells and a Novel Subpopulation Expressing Genes of Both Cell States Contribute to Intra- and Intertumoral Heterogeneity of Primary Melanoma , 2017, Clinical Cancer Research.

[8]  Reinhard Dummer,et al.  Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure , 2017, EMBO molecular medicine.

[9]  N. Haass,et al.  NFIB Mediates BRN2 Driven Melanoma Cell Migration and Invasion Through Regulation of EZH2 and MITF , 2017, EBioMedicine.

[10]  G. Firestone,et al.  Inhibition of oncogenic BRAF activity by indole‐3‐carbinol disrupts microphthalmia‐associated transcription factor expression and arrests melanoma cell proliferation , 2017, Molecular carcinogenesis.

[11]  C. Wellbrock,et al.  The Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin Cancer , 2016, Front. Cell Dev. Biol..

[12]  Charles H. Yoon,et al.  Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq , 2016, Science.

[13]  K. Flaherty,et al.  Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy , 2016, Cancer cell.

[14]  C. Wellbrock,et al.  Microphthalmia‐associated transcription factor in melanoma development and MAP‐kinase pathway targeted therapy , 2015, Pigment cell & melanoma research.

[15]  S. Aerts,et al.  Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state , 2015, Nature Communications.

[16]  T. Graeber,et al.  Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma , 2014, Nature Communications.

[17]  J. Mesirov,et al.  A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. , 2014, Cancer discovery.

[18]  Rajiv Narayan,et al.  A melanocyte lineage program confers resistance to MAP kinase pathway inhibition , 2013, Nature.

[19]  Jun S. Song,et al.  BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition , 2013, Proceedings of the National Academy of Sciences.

[20]  R. Marais,et al.  Effect of SMURF2 Targeting on Susceptibility to MEK Inhibitors in Melanoma , 2012, Journal of the National Cancer Institute.

[21]  S. Ramaswamy,et al.  Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.

[22]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[23]  G. Castellano,et al.  Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase. , 2011, The Journal of investigative dermatology.

[24]  M. Herlyn,et al.  Inverse expression states of the BRN2 and MITF transcription factors in melanoma spheres and tumour xenografts regulate the NOTCH pathway , 2011, Oncogene.

[25]  E. Sahai,et al.  Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A. , 2011, Cancer cell.

[26]  D. Dembélé,et al.  Genome‐wide analysis of POU3F2/BRN2 promoter occupancy in human melanoma cells reveals Kitl as a novel regulated target gene , 2010, Pigment cell & melanoma research.

[27]  C. Fletcher,et al.  The Role of MITF Phosphorylation Sites During Coat Color and Eye Development in Mice Analyzed by Bacterial Artificial Chromosome Transgene Rescue , 2009, Genetics.

[28]  P. Nuciforo,et al.  Brn-2 represses microphthalmia-associated transcription factor expression and marks a distinct subpopulation of microphthalmia-associated transcription factor-negative melanoma cells. , 2008, Cancer research.

[29]  Helen Pickersgill,et al.  Oncogenic BRAF Regulates Melanoma Proliferation through the Lineage Specific Factor MITF , 2008, PloS one.

[30]  G. Cavet,et al.  Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL , 2007, Nature Medicine.

[31]  N. Hayward,et al.  Confirmation of a BRAF mutation-associated gene expression signature in melanoma. , 2007, Pigment cell research.

[32]  I. S. Dunn,et al.  Role of the Mitogen-Activated Protein Kinase Signaling Pathway in the Regulation of Human Melanocytic Antigen Expression , 2006, Molecular Cancer Research.

[33]  D. Schadendorf,et al.  Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. , 2006, Pigment cell research.

[34]  R. Marais,et al.  Elevated expression of MITF counteracts B-RAF–stimulated melanocyte and melanoma cell proliferation , 2005, The Journal of cell biology.

[35]  R. Sturm,et al.  Co-expression of SOX9 and SOX10 during melanocytic differentiation in vitro. , 2005, Experimental cell research.

[36]  M. Herlyn,et al.  Human melanoblasts in culture: expression of BRN2 and synergistic regulation by fibroblast growth factor-2, stem cell factor, and endothelin-3. , 2003, The Journal of investigative dermatology.

[37]  M. Schartl,et al.  Activation of p59Fyn Leads to Melanocyte Dedifferentiation by Influencing MKP-1-regulated Mitogen-activated Protein Kinase Signaling* , 2002, The Journal of Biological Chemistry.

[38]  M. Wegner,et al.  Interaction among SOX10, PAX3 and MITF, three genes altered in Waardenburg syndrome. , 2000, Human molecular genetics.

[39]  M. Schartl,et al.  Activation of phosphatidylinositol 3-kinase by a complex of p59fyn and the receptor tyrosine kinase Xmrk is involved in malignant transformation of pigment cells. , 2000, European journal of biochemistry.

[40]  E. Price,et al.  c-Kit triggers dual phosphorylations, which couple activation and degradation of the essential melanocyte factor Mi. , 2000, Genes & development.

[41]  A. McKenna,et al.  The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. , 2014, Cancer discovery.

[42]  M. Schartl,et al.  Activation of p 59 Fyn Leads to Melanocyte Dedifferentiation by Influencing MKP-1-regulated Mitogen-activated Protein Kinase Signaling * , 2002 .